For twenty years, the mAb platform gave biopharma a reliable formula: similar molecules, reusable process strategies, and predictable regulatory paths. It scaled fast and reduced risk.

But the pipeline has evolved. Multi-specific antibodies, ADCs, fragments, viral vectors, RNA therapeutics, and other emerging modalities now compete for development resources, manufacturing capacity, and regulatory bandwidth. Upstream titers keep climbing, which sounds like progress until you realize the constraint just shifted downstream. Optimizing one unit operation at a time no longer adds up when every decision affects what comes next. The opportunity is to remove friction across the process, connecting development and manufacturing decisions so progress made in one step creates momentum in the next.

In this webinar, Andreas Castan, Director of Upstream Strategic Technologies at Cytiva, makes the case for a different mindset. Not "how do we optimize this step?" but "how do technologies, data, process economics, and regulatory strategy connect across the entire manufacturing workflow?"

You'll walk away with:

• Why the mAb-era manufacturing playbook stalls when pipelines diversify, and what to do about it
• How to evaluate process intensification from a whole-process view, not a unit-operation view
• Where digitalization, PAT, and digital models are creating real value today, and where expectations may still exceed reality
• A framework for aligning development, manufacturing, and regulatory strategy so they accelerate each other instead of competing

The opportunity ahead is real. The future demands manufacturing strategies designed around the connections between technologies, data, processes, and decisions, not simply optimization within each step.

Register now and see where your manufacturing strategy holds, and where it doesn’t